Efficacy of tiotropium&amp;ndash;olodaterol fixed-dose combination in COPD

Derom, Eric; Brusselle, Guy; Joos, Guy

doi:10.2147/copd.s92840

Cited by 16 publications

(17 citation statements)

References 65 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Additive bronchodilator effects of adding LABA such as including olodaterol, 8 vilanterol, 25 and indacaterol 26 had already been reported in COPD patients using LAMA monotherapy. 27 Since LAMA and LABA have different mechanisms of action than that of bronchodilation, 28 , 29 dual-bronchodilator treatment with a LAMA/LABA combination is more effective than doubling the amount of mono bronchodilator in improving pulmonary function and dyspnea. 30 …”

Section: Discussionmentioning

confidence: 99%

<p>First-Line Treatment with Tiotropium/Olodaterol Improves Physical Activity in Patients with Treatment-Naïve Chronic Obstructive Pulmonary Disease</p>

Takahashi

Uchida²,

Kato

et al. 2020

COPD

View full text Add to dashboard Cite

Background Comparative effects on physical activity of mono and dual bronchodilators remain unclear in patients with treatment-naïve chronic obstructive pulmonary disease (COPD). We sought to compare the changes in physical activity before and after tiotropium and tiotropium/olodaterol treatment in treatment-naïve COPD patients. Methods A prospective, multicenter, randomized, open-labeled, and parallel interventional study was conducted. Eighty Japanese patients with treatment-naïve COPD were randomized to receive either tiotropium or tiotropium/olodaterol treatment for 12 weeks. Spirometry and dyspnea index were assessed, and COPD assessment test (CAT) and the 6-minute walk distance (6MWD) were conducted before and after treatment. Evaluation of physical activity was assessed by a triaxle accelerometer over a 2-week period before and after treatment. Results There were no differences in the mean age (69.8 vs 70.4 years), body mass index (BMI) (22.5 vs 22.6 kg/m 2 ) and mean % forced expiratory volume in 1 second (%FEV1) at baseline (61.5 vs 62.6%) between the two groups. Changes in FEV1 (mean±standard error, 242.8±28.8 mL) and transient dyspnea index (TDI) (2.4±0.3 points) before and after tiotropium/olodaterol treatment were greater than with tiotropium treatment (104.1±31.9 mL, p<0.01 and 1.5±0.3, p=0.02, respectively). Changes in the duration of physical activity with 1.0–1.5 metabolic equivalents (METs) estimated in the sedentary position following tiotropium/olodaterol treatment (−38.7±14.7 min) tended to be reduced more than with tiotropium treatment (−4.6±10.6 min) (p=0.06), although those with ≥2.0 METs numerically increased with both treatments (+10.8±7.6 min for tiotropium/olodaterol vs +8.3±7.6 min for tiotropium, p=0.82). Tiotropium/olodaterol treatment reduced the duration of physical activity with 1.0–1.5 METs (regression coefficient, −43.6 [95% CI −84.1, −3.1], p=0.04) in a multiple regression model adjusted for cofounding factors such as age, FEV1, total CAT scores, 6MWD, and TDI. Conclusion This is the first study to report the impact of dual bronchodilator on physical activity in treatment-naïve COPD patients of Japanese with low BMI.

show abstract

Section: Discussionmentioning

confidence: 99%

<p>First-Line Treatment with Tiotropium/Olodaterol Improves Physical Activity in Patients with Treatment-Naïve Chronic Obstructive Pulmonary Disease</p>

Takahashi

Uchida²,

Kato

et al. 2020

COPD

View full text Add to dashboard Cite

show abstract

“…Клиническая эффективность препарата Спиолто Респимат была доказана в ряде РКИ, в которых приняли участие 10 000 пациентов [12].…”

Section: клиническая эффективность препарата спиолто респиматunclassified

Clinical and economic evaluation of using fixed dose dual bronchodilator combination tiotropiumolodaterol in patients with chronic obstructive pulmonary disease

Зырянов¹,

Галатонова²

2018

Med. sov.

View full text Add to dashboard Cite

В настоящее время существенно изменилась концепция лекарственной терапии пациентов с ХОБЛ. Исследования последних лет убедительно демонстрируют преимущества использования двойной бронхолитической терапии при определенных фенотипах ХОБЛ. Данный обзор посвящен анализу клинической и фармакоэкономической эффективности комбинации тиотропия и олодатерола (Спиолто Респимат). Применение Спиолто Респимата у пациентов с ХОБЛ приводит к улучшению спирометрических показателей, снижению одышки, а также улучшению качества жизни, связанного со здоровьем, в сравнении с плацебо, а также с монотерапией тиотропия бромидом (5 мкг) и олодатеролом (5 мкг). Согласно результатам нескольких проведенных в Европе фармакоэкономических исследований «затраты-полезность», применение препарата Спиолто Респимат по показателям полезности превосходит монотерапию тиотропия бромидом (5 мкг). Помимо этого, было выявлено, что Спиолто Респимат является доминантным в сравнении с препаратом Дуаклир Дженуэйр и комбинацией «тиотропия бромид + салметерол», а также идентичным по показателю «затраты-полезность» с препаратами Ультибро Бризхалер и Аноро Эллипта.

show abstract

“…The improvement, although statistically significant, was below the minimal clinically important difference (MCID). 47 …”

Section: Does a Laba/lama Combination Provide Greater Benefits Thamentioning

confidence: 99%

Recommendations for the pharmacological treatment of COPD: questions and answers

et al. 2017

View full text Add to dashboard Cite

The treatment of COPD has become increasingly effective. Measures that range from behavioral changes, reduction in exposure to risk factors, education about the disease and its course, rehabilitation, oxygen therapy, management of comorbidities, and surgical and pharmacological treatments to end-of-life care allow health professionals to provide a personalized and effective therapy. The pharmacological treatment of COPD is one of the cornerstones of COPD management, and there have been many advances in this area in recent years. Given the greater availability of drugs and therapeutic combinations, it has become increasingly challenging to know the indications for, limitations of, and potential risks and benefits of each treatment modality. In order to critically evaluate recent evidence and systematize the major questions regarding the pharmacological treatment of COPD, 24 specialists from all over Brazil gathered to develop the present recommendations. A visual guide was developed for the classification and treatment of COPD, both of which were adapted to fit the situation in Brazil. Ten questions were selected on the basis of their relevance in clinical practice. They address the classification, definitions, treatment, and evidence available for each drug or drug combination. Each question was answered by two specialists, and then the answers were consolidated in two phases: review and consensus by all participants. The questions answered are practical questions and help select from among the many options the best treatment for each patient and his/her peculiarities.

show abstract

Efficacy of tiotropium–olodaterol fixed-dose combination in COPD

Cited by 16 publications

References 65 publications

<p>First-Line Treatment with Tiotropium/Olodaterol Improves Physical Activity in Patients with Treatment-Naïve Chronic Obstructive Pulmonary Disease</p>

<p>First-Line Treatment with Tiotropium/Olodaterol Improves Physical Activity in Patients with Treatment-Naïve Chronic Obstructive Pulmonary Disease</p>

Clinical and economic evaluation of using fixed dose dual bronchodilator combination tiotropiumolodaterol in patients with chronic obstructive pulmonary disease

Recommendations for the pharmacological treatment of COPD: questions and answers

Contact Info

Product

Resources

About